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Abstract
Background: A recent study has shown that treatment of visceral leishmaniasis (VL) with the standard dose of 15 mg/kg/day
of paromomycinsulphate(PM) for21 days wasnotefficaciousinpatients inSudan.Wetherefore decidedtotest the efficacyof
paramomycin for a longer treatment duration (15 mg/kg/day for 28 days) and at the higher doseof 20 mg/kg/day for 21 days.
Methods: This randomized, open-label, dose-finding, phase II study assessed the two above high-dose PM treatment
regimens. Patients with clinical features and positive bone-marrow aspirates for VL were enrolled. All patients received their
assigned courses of PM intramuscularly and adverse events were monitored. Parasite clearance in bone-marrow aspirates
was tested by microscopy at end of treatment (EOT, primary efficacy endpoint), 3 months (in patients who were not
clinically well) and 6 months after EOT (secondary efficacy endpoint). Pharmacokinetic data were obtained from a subset of
patients weighing over 30 kg.
Findings: 42 patients (21 per group) aged between 4 and 60 years were enrolled. At EOT, 85% of patients (95% confidence
interval [CI]: 63.7% to 97.0%) in the 20 mg/kg/day group and 90% of patients (95% CI: 69.6% to 98.8%) in the 15 mg/kg/day
group had parasite clearance. Six months after treatment, efficacy was 80.0% (95% CI: 56.3% to 94.3%) and 81.0% (95% CI:
58.1% to 94.6%) in the 20 mg/kg/day and 15 mg/kg/day groups, respectively. There were no serious adverse events.
Pharmacokinetic profiles suggested a difference between the two doses, although numbers of patients recruited were too
few to make it significant (n=3 and n=6 in the 20 mg/kg/day and 15 mg/kg/day groups, respectively).
Conclusion: Data suggest that both high dose regimens were more efficacious than the standard 15 mg/kg/day PM for 21
days and could be further evaluated in phase III studies in East Africa.
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Introduction
According to the WHO estimates, visceral leishmaniasis (VL) is
a parasitic disease that affects more than 500,000 people globally
each year [1], and has a fatality rate of up to 100% if left untreated
[2]. 90% of cases occur in five countries: India, Bangladesh, Nepal,
Sudan, and Brazil [1], with the affected communities mostly
located in remote regions of these endemic areas without ready
access to treatment.
Although drugs (mainly antimonials such as sodium stibogluco-
nate [SSG]) currently exist to treat this parasitic infection, their use
has been limited because of high cost, toxicity, or development of
parasite resistance [3–5]. A multi-center phase III study in India
showed that PM is a very efficacious, affordable, and safe
treatment [6], and is now registered for VL treatment in India.
In an effort to identify an effective treatment for VL in East
Africa, we had previously initiated a multi-center phase III study
in Sudan, Ethiopia, and Kenya comparing the efficacy of PM
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for 21 days) against SSG alone (20 mg/kg/day for 30 days) and
against a combination treatment of SSG and PM (same dose of
individual treatments but for 17 days). PM monotherapy did not
show adequate efficacy, particularly in Sudan where parasite
clearance was below 50% in patients at 6 months after end of
treatment (EOT), and the study had to be prematurely stopped [7].
In the current study, we sought to find an efficacious dose of PM
for the treatment of VL in Sudan and to explore possible reasons
for the failure of the drug at the previous dose studied of 15 mg/
kg/day for 21 days. In our previous study using this dose,
conducted in 5 sites in Ethiopia, Kenya and Sudan, we found an
overall end of treatment cure of 67.4% and 6-month post-
treatment cure of 63.8% [7]. Cure at both sites in Sudan was
below 50% [7]. The cure rate in this study of SSG was 92.2% at 6
months post-treatment [7].
Therefore a total dose increase of 33% was attempted through
two possible regimens- an increased dose of 20 mg/kg for 21 days
or a prolonged course of 15 mg/kg for 28 days. The former
regimen has been evaluated in some clinical trials in India [8,9].
There was no previous clinical experience with the 15 mg/kg
dosage given for 28 days. The rationale was that the longer course
of treatment would provide additional time for the patient’s
general condition to improve, and for their immunological
response to develop, and that this might translate into a better
clinical response without increasing the daily dosage.
Methods
Study objectives
The main objective was to assess the efficacy of two dosing
regimens of PM monotherapy for the treatment of VL: 20 mg/kg/
day for 21 days and 15 mg/kg/day for 28 days. Secondary
objectives were to assess the safety of PM and compare the
pharmacokinetic (PK) profiles of the two groups in a subset of
patients.
Participants
Patients with clinical symptoms and signs suggestive of VL and
confirmed by visualization of parasites in bone-marrow aspirates
were eligible for enrollment according to the National VL
guidelines for Sudan for treatment and control. To be included
in the study, patients had to: be between 4 and 60 years of age; be
able to comply with the protocol (Protocols S1, S2 and S3); and
provide written informed consent signed by themselves or by
parents or legal guardians.
Patients were excluded from the study if they: had negative
bone-marrow smears; were clinically contraindicated to having a
bone-marrow aspirate; received any anti-leishmania drug in the
past 6 months; had severe protein or caloric malnutrition
(Kwashiorkor or marasmus); had previous hypersensitivity reac-
tion to aminoglycosides; suffered from a concomitant severe
infection, ie tuberculosis, HIV, or any other serious underlying
disease (cardiac, renal, hepatic); suffered from other conditions
associated with splenomegaly such as schistosomiasis; had previous
history of cardiac arrhythmia or an abnormal electrocardiogram
(ECG); were pregnant or lactating; or had pre-existing clinical
hearing loss. If tuberculosis or schistosomiasis were suspected,
these were screened through laboratory testing. Additionally,
patients with the following laboratory values were excluded:
hemoglobin less than 5 g/dL; white blood cell less than 10
3/mm
3;
platelets less than 40,000/mm
3; liver function test values more
than three times the normal range; and serum creatinine values
outside the normal range for age and gender.
Study design
This was a two-arm, randomized, open-label, dose-finding study
done at a single site in Sudan (Kassab Hospital, Ministry of
Health, Gedaref State). This site participated in the previous study
conducted on PM [7]. Eligible patients were randomly assigned to
20 mg/kg/day PM for 21 days (n=21) or 15 mg/kg/day PM for
28 days (n=21), and started a treatment regimen upon allocation
to their treatment. Restricted-block randomization was done for
the two groups. Randomization was done using sequentially
numbered sealed envelopes that were prepared according to a
centrally generated randomization list. Treatment was adminis-
tered via daily intramuscular injection, and patients remained in
the hospital for the duration of treatment. Patients were followed
up at 3 and 6 months after treatment as outpatients. Parasitolog-
ical assessments (bone-marrow aspirates only) were done at
baseline, end of treatment (EOT), 3 months (only on patients
who were not clinically well) and 6 months after treatment. Safety
and clinical laboratory assessments were done at baseline, day 7
and day 14 of drug administration, EOT, and at 3 and 6 months
follow-ups. These included a clinical assessment, (clinical symp-
toms, vital signs, weight, spleen and liver size), ECG, HIV testing
(at baseline only), hemoglobin, white cell count, platelets, urea,
creatinine, liver function tests (bilirubin, aspartate aminotransfer-
ase, alanine aminotransferase, alkaline phosphatase), urinalysis
and audiometry. Audiometry was performed using a standardized
procedure by site investigators who were trained by a qualified
audiometrist and recorded as hearing levels in dB at 0.25, 0.5, 1, 2,
4 and 8 kHz frequencies [10]. All reported abnormal audiometric
readings were reviewed by the audiometrist. An audiometric shift
was defined in patients for whom there was one of the following:
an increase in hearing level between baseline and EOT of $25 dB
at $1 threshold frequency; an increase in hearing level between
baseline and EOT of $20 dB at $2 adjacent threshold
frequencies. Disabling hearing impairment was determined as an
average of at least 41 dB across 0.5, 1, 2 and 4 kHz frequencies in
adults (ages 15 years and above) and at least 31 db across 0.5, 1, 2
and 4 kHz frequencies in children (less than 15 years of age) [10].
Parasitology slides were prepared from bone-marrow aspirates,
read, and reported according to a standardized, approved WHO
method [11,12]. Standardised parasitology readings were done
from freshly prepared bone-marrow aspirates taken directly from
Author Summary
Visceral leishmaniasis (VL) is a parasitic disease transmitted
through the bite of sandflies. The WHO estimates 500,000
new cases of VL each year, with more than 90% of cases
occurring in Southeast Asia, East Africa, and South
America. If left untreated, VL can be fatal. We had
previously conducted a large multi-center study in Sudan,
East Africa, to assess the efficacy of paromomycin (PM)
alone or in combination with sodium stibogluconate.
Clinical studies in India have shown that 15 mg/kg/day PM
for 21 days was an effective cure. However, the same
treatment regimen was not efficacious in two study sites in
Sudan. Here, our aim was to assess two high-dose
regimens of PM in Sudan: 15 mg/kg/day for 28 days and
20 mg/kg/day for 21 days. The results suggest that, at
these total doses, PM is more efficacious than when given
daily at 15 mg/kg for 21 days, and that high doses are
required to treat VL in Sudan. Efficacy of 20 mg/kg/day PM
for 21 days is currently being evaluated in a prospective,
comparative phase III trial in East Africa.
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counted for parasites under oil emersion 1006magnification for
30 minutes (timed) before being declared negative (absence of
parasites on microscopy slide). All parasitology was performed by a
trained laboratory technician.
For the PK analysis, the first six consenting patients weighing
30 kg or more were selected from each treatment group and had
additional venous blood and urine samples on day 1 and day 14 in
the 20 mg/kg/day group, and on day 1 and day 26 in the 15 mg/
kg/day group. The timing for blood sampling was 0 (before
treatment) and at 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours after
administration of the drug, and at 0–2, 2–4, 4–6, 6–8, 8–12, and
12–24 hours after administration of the drug for urine sampling.
Ethics statement
The trial was done in accordance with the Declaration of
Helsinki (2002 version) for the conduct of research on human
subjects and followed the International Committee for Harmoni-
zation guidelines for the conduct of clinical trials. All trial site
personnel received relevant training in Good Clinical Practices.
The Ethics Committee of the Institute of Endemic Diseases,
University of Khartoum, and the Directorate of Health Research,
Federal Ministry of Health, Sudan approved the study protocol
(July 8, 2005), which was submitted as a protocol amendment
(Protocol S3) to our previous study [7].
All participants or their parents or legal guardians gave their
written informed consent before entry into the trial. Children
were included in this study because they represent more than
50% of VL cases in this endemic area, and were included in the
PK sampling if they met the weight criteria (.30 kg). This
study was registered at ClinicalTrials.gov (registration number
NCT00255567).
Treatment
The study medication was 1 g/2mL paromomycin sulphate
(Gland Pharma, India). Doses in the study groups were 20 mg/kg/
day paromomycin sulphate (equivalent to 15 mg/kg/day of
paromomycin base) and 15 mg/kg/day paromomycin sulphate
(equivalent to 11 mg/kg/day paromomycin base). The rescue
medication was AmBisome (a liposomal formulation of ampho-
tericin B, Gilead, USA), which was reconstituted according to the
manufacturer’s instructions for a dosage of 3 mg/kg/day for 10
days.
Outcome measurements
Efficacy. The primary efficacy endpoint was cure (parasite
clearance) at EOT (i.e., on days 22 and 29 for 20 mg/kg PM and
15 mg/kg PM, respectively). The secondary efficacy endpoint was
parasite clearance at 6 months follow-up.
Efficacy was reported as the number and percentage of
randomized patients in whom no parasites were detected by arm
at each endpoint. Rescue medication before an endpoint indicates
treatment failure at that endpoint. Clinical and biological
parameters, such as temperature, weight, spleen size and
hemoglobin, were used by clinicians to decide each patient’s
response to treatment and whether rescue medication was
indicated. Relapse at 3-month follow-up was defined as patients
with no parasites detected at EOT but in whom parasites were
seen at 3-month follow-up. Slow response to treatment was
defined as the presence of parasites at EOT but not at 6 months in
the absence of rescue medication. Therefore, a treatment failure at
initial test of cure (EOT) that did not receive rescue medication
was defined as a slow responder so long as there was parasite
clearance at 6-month follow-up.
Safety. Safety analyses were based on the number of adverse
events (AEs) that occurred during the study, including changes of
pre-defined magnitudes in audiometric measurements (a known
side-effect of aminoglycosides [13]) and abnormal clinical
laboratory or vital sign measurements. AEs were rated for
seriousness, severity, and causality by the site investigator and
were coded using the Medical Dictionary of Regulatory Activities
(MedDRA), version 10.0.
Audiometric shift and disabling hearing impairment were
defined according to an earlier phase III trial [6] and WHO
guidelines [10].
Pharmacokinetics. For the PK study, only patients with
body weight of more than 30 kg were included. PM was assayed
using high-performance liquid chromatography, as described
previously [14] with some modifications.
Statistical methods. The study was not powered to detect
differences between the groups; indeed, the study objective was to
assess whether improved efficacy without increasing risk could be
obtained by using either a higher dose or an increased treatment
duration of PM. A precision estimate for 21 patients would allow
estimation of efficacy such that the lower bound of the 95%
confidence interval around the efficacy estimate will be at least
60% for 17 or more treatment successes (efficacy at least 81%).
Analyses were carried out using Stata, version 10 (Stata
Corporation, College Station, Texas). Analyses were done on
the intention-to-treat (ITT) population. In case of missing data,
efficacy analyses were by complete-case analysis, excluding
patients with missing data, and by worst-case analysis, where
missing efficacy data are assumed to be treatment failures. To
account for different treatment durations and avoid overestimating
harm in the longer treatment duration group, the treatment-
emergent adverse event (TEAE) rate was calculated, per group, as
the total number of adverse events divided by the total person-time
at risk [15,16]. The total person-time at risk for TEAE in each
group was defined as the number of randomized patients
multiplied by the treatment duration in days plus 30 days (51
days in the group of PM 20 mg/kg for 21 days and 58 days in the
group of PM 15 mg/kg for 21 days).
Results
Study population
104 patients with suspected VL were screened for entry into this
study. Of these, 42 patients were enrolled in the study (21 per
group; figure 1). Demographics and baseline characteristics were
similar in the two groups (table 1). One patient in the 20 mg/kg/
day PM group was considered lost by the 6-month follow-up. The
first patient was recruited in October 2005 and the last patient
followed-up in October 2006.
Efficacy
Data were available for all patients at EOT (figure 1). 18
patients in the 20 mg/kg group and 19 in the 15 mg/kg group had
parasite clearance at EOT, indicating an efficacy of 85.7% (95%
CI: 63.7% to 97.0%) and 90.5% (95% CI: 69.6% to 98.0%),
respectively (table 2).
At 3-months follow-up, two patients had relapsed in the 20 mg/
kg/day for 21 days regimen and three in the 15 mg/kg/day for 28
days regimen; however, there were no additional relapses at 6
months. At 6-months follow-up, the complete-case analysis efficacy
in both groups was similar (80.0% in the 20 mg/kg/day group
versus 81.0% in the 15 mg/kg/day group) (table 2). All treatment
failures were given rescue medication. An exception was one
patient in the 20 mg/kg/day PM group who was parasite positive
Paromomycin Dose-Finding Study for VL
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at 6 months, leading to a lower efficacy estimate in the worst-case
analysis (table 2). There was one slow responder (ie, parasite-
positive patient at EOT, but clinically well and ultimately
recovered) in the group treated with 15 mg/kg/day PM for 28
days.
Safety
PM was well tolerated in this study. 48 AEs were reported in
total; 20 in the 20 mg/kg for 21 days group and 28 in the 15 mg/
kg for 28 days group (table 3), and none was regarded as serious.
This gives an AE rate of 0.05 per person-day on treatment in both
groups. All AEs, except diarrhea and malaria, were judged to be
related to the treatment. The most frequent AE was injection site
pain (n=33). Audiometric shifts were seen in five patients at EOT
(n=3 in the 15 mg/kg group and n=2 in the 20 mg/kg group),
but completely resolved by 6 months follow-up. Disabling hearing
impairment, detected at EOT, which improved but persisted at 6
months (ie still met the criteria for audiogram shift), occurred in
one patient in the 20 mg/kg group.
Pharmacokinetics
Although six patients from each group should have taken part in
the PKstudy, only data from three patients in the 20 mg/kg/day PM
group and six in the 15 mg/kg/day PM group were obtained. Only
one patient was a child (age of 12 years and weight of 39 kg in the
15 mg/kg group). The others were aged between 17 and 28 years.
Mean plasma PM concentrations at the earlier time points were
similar between the two treatment groups (figure 2). Nevertheless,
the peak mean plasma PM concentration on day 1 was slightly
higher in the 20 mg/kg/day group compared with that in the
15 mg/kg/day group (7.864.9 mg/mL versus 5.664.2 mg/mL).
Six hours after administration, PM was not detected in the plasma
of patients receiving 15 mg/kg/day PM but was seen at
concentrations slightly lower than peak in the plasma of patients
receiving 20 mg/kg/day PM (figure 2).
Discussion
To date,the standard treatment for VLin East Africa still consists
of antimonials. This study is part of the first large-scale multi-centre
clinical trial to assess the efficacy of PM for the treatment of VL for
the East African region. The initial study [7] showed poor efficacy
results when 15 mg/kg/day PM was administered for 21 days to
VL patients. This finding is in contrast to an earlier phase III study
in India [6]. The results of this study show that increasing the total
dose of PM from 15 mg/kg/day for 21 days to 15 mg/kg/day for
28 days or 20 mg/kg/day for 21 days improves efficacy in VL
patients in Sudan. However, it should be cautioned that the results
found in this study apply to one site only and might not apply to the
whole East African region.
Although efficacy is normally assessed as parasite clearance at 6
months in trials for VL, in this study we chose to use parasite
clearance at EOT as the primary endpoint because a chance of
loss to follow-up of just a few patients would significantly affect the
result. In addition to the small sample size, another potential
limitation is the use of bone-marrow aspiration for diagnosis and
test of cure. However, spleen aspiration remains contraindicated in
Figure 1. Flowchart of patients.
doi:10.1371/journal.pntd.0000855.g001
Paromomycin Dose-Finding Study for VL
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alternative.
At 6 months after treatment, efficacy was 80.0% (95% CI:
56.3% to 94.3%) and 81.0% (95% CI: 58.1% to 94.6%) in the
20 mg/kg/day and 15 mg/kg/day groups, respectively, compared
with less than 50% (in Sudan) at 6 months observed in the
previous study [7]. This result shows that efficacy improved to
levels closer to those obtained in trials in India (,95%) [6].
Table 1. Baseline characteristics.
20 mg/kg/day PM for 21 days (N=21) 15 mg/kg/day PM for 28 days (N=21)
Age (years) 19.4 (12.3) 17.7 (9.8)
4–14 years 10 (47.6%) 8 (38.1%)
15–60 years 11 (52.4%) 13 (61.9%)
Sex (male) 16 (76.2%) 19 (90.5%)
Nutritional status*
Severely underweight 2 (9.5%) 0
Underweight 10 (47.6%) 13 (61.9%)
Normal 9 (42.9%) 8 (38.1%)
Weight 36.5 (16.5) 40.0 (16.8)
Temperature (uC) 38.9 (0.6) 39.0 (0.6)
Heart rate (beats/min) 106.2 (13.2) 105.4 (12.1)
Spleen size (cm) 5.9 (3.3) 5.5 (3.6)
Liver size (cm) 2.9 (3.0) 3.0 (2.0)
Systolic BP (mm Hg) 100.7 (12.1) 99.0 (12.6)
Diastolic BP (mm Hg) 61.9 (9.7) 59.8 (10.4)
Log scale parasite count,
6+ 4 (19.1%) 1 (4.8%)
5+ 00
4+ 1 (4.8%) 2 (9.5%)
3+ 1 (4.8%) 2 (9.5%)
2+ 1 (4.8%) 4 (19.1%)
1+ 14 (66.7%) 12 (57.1%)
Hemoglobin (g/dL) 7.6 (1.4) 7.7 (0.9)
White-cell count (610
3/mL) 3.1 (1.2) 2.8 (0.9)
Platelets (610
3/mL) 311.6 (165.8) 251.7 (89.5)
AST (U/L) 18.8 (5.3) 19.9 (5.2)
ALT (U/L) 18.1 (4.5) 18.8 (4.7)
Bilirubin (mmol/L) 12.0 (5.8) 14.0 (10.4)
BUN (mmol/L) 9.7 (3.1) 9.5 (3.8)
Creatinine (mmol/L) 55.1 (15.8) 64.4 (19.4)
Data are mean (SD) or n (%).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; BUN, blood urea nitrogen.
*Based on Weight for Height (WHO child growth standards) if age ,6 years) and BMI for Age if age 6–19 years; defined as severely underweight if z-score,23SD;
underweight if 23SD#z-score ,22SD; normal if 22SD#z-score,+1SD; and BMI if age .19 years: defined as severely underweight if ,16, underweight: 16.0–18.4,
normal: 18.5–24.9.
doi:10.1371/journal.pntd.0000855.t001
Table 2. Complete-case efficacy analysis.
20 mg/kg/day PM for 21 days (N=21) 15 mg/kg/day PM for 28 days (N=21)
End of treatment 18/21 (85.7%)
95% CI: 63.7–97.0%
19/21 (90.5%)
95% CI: 69.6–98.8%
6-month follow-up* 16/20 (80.0%)
95% CI: 56.3–94.3%
17/21 (81.0%)
95% CI: 58.1–94.6%
Data are n (%). CI, confidence interval.
*One patient lost to follow-up at 6 months in the 20 mg/kg group: worst-case efficacy=16/21 (76.2%, 95% CI: 52.8–91.8%).
doi:10.1371/journal.pntd.0000855.t002
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high doses were not identified in this study. Otoxicity, which has
been seen as a transient side-effect of PM in other studies [6], was
also identified as a potential issue in this study because one patient
had audiometric shift at 6 months. This shift occurred at high
frequencies, as expected with aminoglycosides [6]. We suggest that
this adverse event needs to be monitored closely in subsequent
studies.
PK analyses showed that peak plasma PM concentration
occurred 1–2 hours after administration and suggest that, at the
high daily dose of 20 mg/kg, elevated plasma PM concentrations
may be maintained for a longer period of time (up to 8 hours).
Unpublished data (Mahmoud Mudawi, personal communication)
of PM administration (15 mg/kg) to healthy Sudanese volunteers
showed peak PM plasma concentrations similar to those in
American volunteers who received a similar dose [14]. Sudanese
VL patients had a much lower plasma concentration (30–40%)
than that of healthy Sudanese (19.567.6mg/mL; n=6) and
American volunteers. Therefore, Sudanese VL patients may have
different PK characteristics from both Sudanese and American
Table 3. Non-serious adverse events.
Events 20 mg/kg/day PM for 21 days (N=21) 15 mg/kg/day PM for 28 days (N=21)
Diarrhea 1 (4.8%) 0
Injection site pain 14 (66.7%) 16 (76.2%)
Abnormal audiogram 3 (14.3%) 3 (14.3%)
Malaria 1 (4.8%) 1 (4.8%)
Acute otitis media 0 1 (4.8%)
PKDL 1 (4.8%) 4 (19.0%)
Epitaxis 0 1 (4.8%)
Cholestatic jaundice 0 1 (4.8%)
Jaundice 0 1 (4.8%)
Total 20 28
Data are n (%) of AEs reported. PKDL, Post-kala-azar dermal leishmaniasis.
doi:10.1371/journal.pntd.0000855.t003
Figure 2. Semi-log plot of mean (SD) paromomycin (PM) concentrations (mg/mL) versus time (hours) after a single intramuscular
injection. Plasma PM concentrations on day 1 (D1), day 14 (D14), and day 26 (D26) for VL patients who received either 15 mg/kg (n=6) or 20 mg/kg
PM (n=3).
doi:10.1371/journal.pntd.0000855.g002
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were very limited and derived from only a small subset of patients.
A PK study with more patients is currently underway as part of the
larger phase III study.
Even though interpretation of our results is limited because of
the small sample size, we identified what seems to be a more
efficacious dose of PM than the one previously used in Sudan [7].
A meeting of the principal investigators was held to discuss the PM
efficacy and PK dose-finding results. The group chose to use in the
large multi-center phase III study, a dose of 20 mg/kg/day for 21
days for a comparison with the previously used doses of SSG and
SSG and PM in combination. Our initial study [7] showed that
efficacy of PM can vary greatly between geographical regions, and
in addition to this study, suggests that different doses may be
required to obtain similar levels of efficacy. If confirmed, these
results emphasize the importance of considering regional differ-
ences in the treatment of VL and show that drugs of proven
efficacy in Asian patients might not have the same efficacy in
African patients.
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